Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab in Advanced Solid Tumors
NCT02937116Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Oct 2016
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of sintilimab in solid tumor, melanoma, gastrointestinal carcinoma and 4 more (9 arms), sponsored by Innovent Biologics. Primary endpoints: Dose-limiting Toxicities at 28 days, Tumor Response at 2 years and 1 more. Started Oct 2016; status: completed.
02
Drugs
sintilimab
03
Conditions
solid tumormelanomagastrointestinal carcinomanon-small cell lung cancer (NSCLC)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT02937116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02937116.